Innate Pharma (IPH) Leerink’s Global Healthcare Conference 2025 summary

Leadership and strategic focus

• New CEO and COO bring extensive experience from major pharma and biotech, emphasizing a renewed focus on the ANKET platform and ADCs, with plans to partner the lead asset, lacutamab.

• Strategy updates include prioritizing differentiated technologies and rapid execution in clinical development.

ADC program (IPH4502) insights

• IPH4502 is a Nectin-4 directed ADC with a unique epitope and exatecan payload, targeting low-expressing tumors and offering a different resistance profile from competitors.

• Hydrophilic linker technology aims to improve safety and efficacy; rapid clinical execution demonstrated by fast patient dosing post-IND clearance.

• Encouraging external data from China supports the sequential use of different ADC payloads and highlights a strong therapeutic index.

• Study design allows for signal-driven expansion across multiple tumor types, with first data expected late this year or early next.

Regulatory and clinical development (Lacutamab)

• Lacutamab received breakthrough designation, with regulatory alignment for a phase 3 study in Sezary syndrome and mycosis fungoides, including earlier lines of therapy.

• Finalized phase 3 design expected by mid-year, with patient recruitment targeted for late 2024 or early 2025.

• Company remains open to partnering but is prepared to advance independently if necessary.

• Biomarker analyses suggest potential for broader indications and patient stratification.